Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer/Onyx BAY 43-9006 Interim Analysis To Support Accelerated NDA Filing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Onyx expects its kidney cancer therapy BAY 43-9006 to receive accelerated approval by 2006 based on initial Phase III data showing statistically significantly longer progression-free survival versus placebo

You may also be interested in...

Bayer/Onyx, Pfizer Submit NDAs For Fast-Track Kidney Cancer Agents

Bayer and Onyx expect to launch their renal cell carcinoma therapy BAY 43-9006 (sorafenib) in the first half of 2006

Bayer/Onyx will wait for kidney oncologic Phase III data

Bayer/Onyx plan to wait for Phase III overall survival results for their kidney cancer agent BAY 43-9006 instead of moving forward with submission using Phase II data, which will push launch projections back to 2006. Bayer outlined a plan to file based on the Phase II results when the data was presented at the American Society of Clinical Oncology meeting in June. The firms expect to enroll 800 renal cell carcinoma patients in the Phase III trial of the RAF kinase inhibitor, now underway. The trial "was initiated after a special protocol assessment was completed by the FDA in the fourth quarter of 2003," Onyx says Oct. 25...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts